Israel - Hebrew - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii

Israel - Hebrew - Ministry of Health

eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab

Israel - Hebrew - Ministry of Health

sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.

Israel - Hebrew - Ministry of Health

padagis israel agencies ltd, israel - labetalol hydrochloride - טבליה - labetalol hydrochloride 100 mg - labetalol - labetalol - treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.

Israel - Hebrew - Ministry of Health

j-c health care ltd - oxybutynin chloride - טבליות בשחרור ממושך - oxybutynin chloride 5 mg - oxybutynin - oxybutynin - once daily controlled-release tablet indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Israel - Hebrew - Ministry of Health

j-c health care ltd - oxybutynin chloride - טבליות בשחרור ממושך - oxybutynin chloride 10 mg - oxybutynin - oxybutynin - once daily controlled-release tablet indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Israel - Hebrew - Ministry of Health

organon pharma israel ltd., israel - betamethasone as dipropionate; betamethasone sodium phosphate - תרחיף להזרקה - betamethasone sodium phosphate 2 mg/ml; betamethasone as dipropionate 5 mg/ml - betamethasone - betamethasone - produces anti-inflammatory, anti rheumatic and anti-allergic action and is indicated for systemic and local therapy of acute and chronic corticosteroid-responsive disorders.

Israel - Hebrew - Ministry of Health

glaxo smith kline (israel) ltd - aciclovir - אבקה להכנת תמיסה לאינפוזיה - aciclovir 250 mg/vial - aciclovir - aciclovir - for the treatment of herpes simplex infections and severe initial genital herpes in the non immunocompromised. for the prophylaxis of herpes simplex infections in immune-compromised patients. in the treatment of varicella zoster infections. for herpes simplex encephalitis. for the treatment of herpes simplex infection in the neonate and infant up to 3 months of age.

Israel - Hebrew - Ministry of Health

j-c health care ltd - darunavir as ethanolate - טבליות מצופות פילם - darunavir as ethanolate 75 mg - darunavir - darunavir - adult patients : prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv -1) infection. this indication is based on analyses of plasma hiv rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment - naive and treatment -experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment -experienced adult patients .pediatric patients :prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of hiv in pediatric patients 6 years of age and older. this indication is based on week 24 analyses of plasma hiv rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment -experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric the following points should be considered when ini

Israel - Hebrew - Ministry of Health

j-c health care ltd - darunavir as ethanolate - טבליות מצופות פילם - darunavir as ethanolate 150 mg - darunavir - darunavir - adult patients : prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv -1) infection. this indication is based on analyses of plasma hiv rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment - naive and treatment -experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment -experienced adult patients .pediatric patients :prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of hiv in pediatric patients 6 years of age and older. this indication is based on week 24 analyses of plasma hiv rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment -experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric the following points should be considered when ini